Treatment of high-risk neuroblastoma
Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trial...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Pediatric Society
2012-04-01
|
| Series: | Korean Journal of Pediatrics |
| Subjects: | |
| Online Access: | http://kjp.or.kr/upload/pdf/kjped-55-115.pdf |